October 2021
Starting from:
£99 + VAT
Format: DOWNLOADABLE PDF
This conference examined the priorities outlined in the Cancer Services Recovery Plan and how best to support cancer care and diagnosis - as well as priorities for innovation and the Cancer Drugs Fund going forward.
It was an opportunity to consider the potential impact of NHS reform on underpinning long-term ambitions for cancer, with the Government’s Health and Care Bill aiming to support the integration of health and care in local areas and build upon innovative developments made during the pandemic in order to drive forward the delivery of the NHS Long Term Plan.
The discussion also took place following the publication of The Forgotten C: The Impact of COVID-19 on Cancer Patients from Macmillan Cancer Support, which outlines concerns over the backlog resulting from the pandemic and makes several recommendations for the Government.
We are very pleased to have been able to include keynote addresses from:
- Professor Peter Clark, Clinical Lead for the Cancer Drugs Fund, NHS England
- Professor Anne Mackie, Director of Screening, Public Health England
- Dr Ian McKay, Innovation Lead for Advanced Therapies, Innovation UK
- Amanda Pleavin, Managing Director, East of England Cancer Alliances and COVID-19 Cancer Recovery Lead, NHS England and NHS Improvement - East of England.
It was chaired by The Rt Hon Lord Lansley, Former Secretary of State for Health.
The agenda brought out latest thinking on:
- priorities for service restoration - assessing priorities, plans, and progress, as well as looking at the impact of the pandemic on a range of aspects of cancer diagnosis, treatment, and care
- NHS reforms - the role of reform in cancer service delivery and priorities for the Cancer Recovery Programme and the NHS Long Term Plan
- funding and investment - assessing the current landscape for funding and priorities for the Cancer Drugs Fund
- innovation - next steps for developments in medicine and technology for cancer treatment and improving patient outcomes
Attendees
Our forums are known for attracting strong interest from policymakers and stakeholders. Places were reserved by officials from the Department of Health, NI; the Department for International Trade; the Foreign, Commonwealth & Development Office; the Medicines and Healthcare products Regulatory Agency; the National Audit Office; and the Welsh Government. Representatives who also attended were from AstraZeneca; B. Braun Medical; Boehringer Ingelheim; Fight Bladder Cancer; Frontier Economics; GlaxoSmithKline; Guardant Health; Healthwatch Worcestershire; Incisive Health; IPATHDIGITAL Community Interest Company; Ipsen; Kheiron Medical Technologies; Lilly; Macmillan Cancer Support; MSD; National Institute for Health Research; NHS Wales Collaborative; NICaN; Northumbria Healthcare; Oncimmune; Pancreatic Cancer UK; Pfizer; Pierre Fabre; Public Health England; Public Health Scotland; Roche; Salivary Gland Cancer UK; Sanofi UK; Si-Health; Society of Radiographers; The Royal College of Pathologists; The Society and College of Radiographers; and Varian Medical Systems UK.
A press pass had been reserved by a representative from APM Health Europe.
Overall, we expected speakers and attendees to be a senior and informed group including Members of both Houses of Parliament, senior government and regulatory officials involved in this area of policy, as well as representatives from the NHS, executive agencies including clinical staff, regulators, local authorities, the independent and third sectors, patient groups, pharmaceutical companies, research and development, law firms, consultancies, and others affected by the issues discussed as well as academics and think tanks, together with reporters from the national and specialist media.
